A microbiome-derived metabolite from Staphylococcus epidermidis inhibits Staphylococcus aureus biofilm formation and virulence
- 1University of Kansas
Abstract
Staphylococcus epidermidis is a common member of the healthy skin microbiome that contributes to barrier function and protection against pathogen colonization. In contrast, Staphylococcus aureus is a major human pathogen and the leading cause of skin and soft tissue infections, owing in part to its robust biofilm-forming capacity and increasing antimicrobial resistance. We previously demonstrated that S. epidermidis cell-free conditioned media (CFCM) inhibit S. aureus biofilm formation by altering bacterial gene expression without affecting growth. Here, we identify the metabolite responsible for this activity. Bioactivity-guided fractionation of S. epidermidis CFCM revealed pyroglutamic acid (PCA) as the active antibiofilm compound. Commercially sourced PCA inhibited S. aureus biofilm formation and reduced adhesion to epithelial cells. In a murine skin infection model, PCA treatment significantly attenuated disease severity, accelerated wound healing, and reduced bacterial burden. Analysis of S. epidermidis CFCM by chromatography, nuclear magnetic resonance spectroscopy, and mass spectrometry confirmed the presence of PCA and identified it as the bioactive constituent responsible for antibiofilm activity. Together, these findings uncover a previously unrecognized mechanism by which S. epidermidis suppresses S. aureus virulence and highlight the potential of microbiome-derived metabolites as therapeutics for the prevention and treatment of S. aureus skin infections.
Related
- Staphylococcus aureus in bovine mastitis in northwestern Iran: patterns of antimicrobial and multidrug resistance, biofilm formation, and virulence/resistance gene carriage
- Colonization with human-derived Staphylococcus epidermidis is associated with altered local burden and tissue dissemination of Borrelia burgdorferi sensu stricto in C3H/HeN mice
- The diadenosine tetraphosphate hydrolase YqeK controls fitness, biofilm formation, staphyloxanthin production and virulence in Staphylococcus aureus
- Corneal epithelial signals remodel bacterial physiology and extracellular vesicle cargo in Pseudomonas aeruginosa and Staphylococcus epidermidis
- Metagenomic next-generation sequencing of aqueous humor guides targeted therapy for Staphylococcus epidermidis endophthalmitis in chronic ocular graft-versus-host disease: a case report
BibTeX
@misc{sood2026microbiomederived,
title = {{A microbiome-derived metabolite from Staphylococcus epidermidis inhibits Staphylococcus aureus biofilm formation and virulence}},
author = {A. Sood and K. Hajiarbabbi and W. R. Ribeiro and A. C. Oliveira and L. C. M. Antunes and R. B. R. Ferreira},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.23.753553},
url = {https://www.biorxiv.org/content/10.64898/2026.09.23.753553v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - A microbiome-derived metabolite from Staphylococcus epidermidis inhibits Staphylococcus aureus biofilm formation and virulence
AU - A. Sood
AU - K. Hajiarbabbi
AU - W. R. Ribeiro
AU - A. C. Oliveira
AU - L. C. M. Antunes
AU - R. B. R. Ferreira
PY - 2026
DA - 2026/09/23
PB - bioRxiv
DO - 10.64898/2026.09.23.753553
UR - https://www.biorxiv.org/content/10.64898/2026.09.23.753553v1
AB - Staphylococcus epidermidis is a common member of the healthy skin microbiome that contributes to barrier function and protection against pathogen colonization. In contrast, Staphylococcus aureus is a major human pathogen and the leading cause of skin and soft tissue infections, owing in part to its robust biofilm-forming capacity and increasing antimicrobial resistance. We previously demonstrated that S. epidermidis cell-free conditioned media (CFCM) inhibit S. aureus biofilm formation by altering bacterial gene expression without affecting growth. Here, we identify the metabolite responsible for this activity. Bioactivity-guided fractionation of S. epidermidis CFCM revealed pyroglutamic acid (PCA) as the active antibiofilm compound. Commercially sourced PCA inhibited S. aureus biofilm formation and reduced adhesion to epithelial cells. In a murine skin infection model, PCA treatment significantly attenuated disease severity, accelerated wound healing, and reduced bacterial burden. Analysis of S. epidermidis CFCM by chromatography, nuclear magnetic resonance spectroscopy, and mass spectrometry confirmed the presence of PCA and identified it as the bioactive constituent responsible for antibiofilm activity. Together, these findings uncover a previously unrecognized mechanism by which S. epidermidis suppresses S. aureus virulence and highlight the potential of microbiome-derived metabolites as therapeutics for the prevention and treatment of S. aureus skin infections.
ER -